MRKR Marker Therapeutics, Inc.

NASDAQ
$1.15

Marker Therapeutics, Inc. (MRKR) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.12 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.9% since its last earnings release on August 14, 2026.

Marker Therapeutics Beat Consensus Estimates
Friday, August 14, 2026 · 12:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · After Close
Earnings Whisper
-
vs ($0.12)
Rev est $2.45M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.29

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T Cell Therapy, TPIV200 and TPIV100/110 which are in clinical stage. Marker Therapeutics Inc., formerly known as TapImmune Inc., is based in FL, United States.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.